1. Introduction {#s0005}
===============

Although of the tremendous advance in technology and health sciences, drug interaction is still vexatious for the national health system, and it may lead to deleterious sequelae ([@b0145]). It's estimated that approximately 5% of the adverse effects in hospitals, and around 11% of the prescribed medications in the out-patient settings are attributed to potential drug interactions ([@b0040], [@b0140]). Nationally, about 0.6% of all hospital admissions were accounted for drug-drug interactions (DDIs) while in Saudi Arabia almost 7% of all hospital admissions due to drug-related problems were attributed to DDIs, most of these interactions happened among elderly population ([@b0005], [@b0030]). The physiological changes that affect pharmacokinetics and pharmacodynamics, and the high incidence of polypharmacy make elderly population vulnerable subjects for potential impact of drug interactions ([@b0095]).

Beside the DDIs, drug interactions can manifest as drug-disease, or drug-dietary/herbal supplement interactions ([@b0065]). St. John\'s wort, a widely used herbal supplement as an antidepressant, is associated with numerous drug interactions ([@b0150]). Also, drug interactions can be dose or time dependent interactions ([@b0045], [@b0130]). For example, it's highly recommended to limit the dose of simvastatin to 20 mg per day when co-administered with amlodipine or diltiazem to halt the incidence of myopathy ([@b0130]). It's also recommended to separate the administration time of oral fluoroquinolones and oral divalent or trivalent cation-containing compounds to prevent the antibiotic failure ([@b0045]).

Many national clinical practical guidelines such as Centers for Disease Control and Prevention, American Headache Society, American Heart Association, American College of Cardiology, American College of Gastroenterology and others provide recommendations regarding some of common drug interactions ([@b0030], [@b0035], [@b0055]). In addition, several epidemiologic studies have shown the risk of harm with specific drug interactions and discussed the intensity of those kinds of interactions ([@b0015], [@b0020], [@b0025], [@b0050], [@b0060], [@b0070], [@b0105]). However, the knowledge and attitude towards drug interactions don't appear to be studied sufficiently. The published studies were either evaluated the knowledge among only prescribers or interns ([@b0090], [@b0110]). Pharmacists, especially in the community settings, are in the front lines to detect DDIs, but unfortunately, they were not the main target in these published studies. In addition, assessing the knowledge of drug interactions in Saudi Arabia seems missing. Evaluating and then improving the knowledge of potential common DDIs among community pharmacists (CPs) by implementing useful programs will limit the incidence of deleterious adverse effects, emergency visits, hospital admissions, and certainly health cost. The aim of our study was to evaluate the knowledge of potential common DDIs among community pharmacists particularly in Saudi Arabia.

2. Methods {#s0010}
==========

2.1. Design {#s0015}
-----------

A cross-sectional study was conducted using a self-administered questionnaire. The questionnaire was carried over a period of 6 months from November 2014 to May 2015. This study involved all community pharmacy outlets (including chain and independent pharmacies) in Riyadh city, Saudi Arabia.

2.2. Sample selection {#s0020}
---------------------

The online calculator (Raosoft Inc) was used to estimate the study sample size. According to a previous study, number of community pharmacies in Riyadh city in August 2013 reached 1700 pharmacies ([@b0010]). This study used the rate tolerates of 5%, and 95% confidence levels to give 314 pharmacies. This study involved 350 community pharmacies by a stratified random sampling.

2.3. Survey questionnaire {#s0025}
-------------------------

The questionnaire used was consisted of two sections; the first section was related to demographic data and included age, length of experience and country of graduation. The second section was about assessing the knowledge of CPs about DDIs. The DDIs questionnaire was designed and developed from previous studies that assessed the knowledge of health care professionals about DDIs ([@b0075], [@b0110], [@b0120]). The questionnaire consisted of 26 drug pairs, those pairs were the most common DDIs found in published literature ([@b0075], [@b0110], [@b0120]). CPs were asked to classify the DDIs as "contraindication", "may be used together with monitoring", "no interaction" and "not sure". Among the 26 drug pairs, nine were contraindicated (warfarin with cimetidine, sildenafil with isosorbide mononitrate, pimozide with ketoconazole, itraconazole with quinidine, methotrexate with probenecid, amiodarone with fluconazole, meperidine with phenelzine, alprazolam with itraconazole, and cprofloxacin with tizanidine). It also contained eleven drug pairs that can be used with monitoring and six drug pairs that had no known interactions. Any correct answer for the DDIs questions was given 1 point. Then scores were calculated by counting all the corrected answers with the maximum score of 26.

2.4. Ethical approval {#s0030}
---------------------

The ethical approval was optioned from The King Saud University's institutional review broad.

2.5. Data analysis {#s0035}
------------------

The data were entered into SPSS software version 24 for analysis. Both descriptive and analytic statistics were applied. For descriptive analysis, results were presented as numbers, percentages, and mean (±SD). The Kruskal-Wallis test was used to determine differences between CPs demographic data in knowledge scores at a significance level of 0.05.

3. Results {#s0040}
==========

A total of [283 CPs]{.ul} returned the survey with response rate of 80.9%. About two-third of the participants were between 25 and 35 years old. About half of respondents have an experience in the field of pharmacy for less than 10 years. More than one-third of respondents have been graduated from schools of pharmacy in Egypt ([Table1](#t0005){ref-type="table"}).Table 1Demographic characteristics of the study participants (n = 283[\*](#tblfn1){ref-type="table-fn"}).Demographic dataNumber of participantsPercentage (%)Age25--3518264.336--458028.346--55124.2  Years of practiceless than 10 years14251.811--2012043.821--3093.331--4031.1  Country of graduationEgypt19167.5Sudan72.5Yemen4817Saudi Arabia11(3.9)3.9Others8(2.8)2.8[^1]

3.1. Knowledge of community pharmacist of DDIs {#s0045}
----------------------------------------------

The responses of the 26 DDIs knowledge questions are summarized in [Table 2](#t0010){ref-type="table"}. The study found that the lowest correct response of DDIs was between amiodarone and fluconazole (16.3%) and the highest was between sildenafil and isosorbide mononitrate (74.6%). In most of incorrect responses "may be used together with monitoring" were chose more by 8 times followed by "shouldn't be used together" by 6 times.Table 2Frequencies and percentages of respondents to potential DDIs[\*](#tblfn2){ref-type="table-fn"}Drug --drug combinationsShouldn't be used together Contra indication) n(%)May be used together with monitoring n(%)No interactions n(%)Not sure n(%)Warfarin and cimetidine**169 (59.7)**81 (28.6)21(7.4)12(4.2)Sildenafil and isosorbide mononitrate**211(74.6)**64(22.6)6(2.1)2(0.7)Conjugated estrogens and raloxifen66(23.3)112(39.6)**77(27.2)**28(9.9)Fexofenadine HCL and metoprolol38(13.4)84(29.7)**124(43.8)**37(13.1)Theophylline and ciprofloxacin113(39.9)**99(35)**53(18.7)18(6.4)Pimozide and ketoconazole**92(32.5)**127(44.9)21(7.4)43(15.2)Methyldopa and phenobarbital127(44.9)80(28.3)**50(17.7)**26(9.2)Phenytoin and cimetidine148(52.3)**87(30.7)**23(8.1)25(8.8)Itraconazole and quinidine**107(37.8)**105(37.)28(9.9)42(14.9)Amiodarone and simvastatin72(25.4)**122(43.1)**63(22.3)26(9.2)Methotrexate and probenecid**60(21.2)**120(42.4)54(19.1)47(16.7)Diphenhydramine and warfarin45(15.9)122(43.1)**87(30.7)**29(10.2)Raloxifene and alendronate30(10.6)120(42.4)**91(32.2)**39(13.8)Warfarin and diflunisal82(29.0)**106(37.5)**31(11.0)64(22.6)Amiodarone and fluconazole**46(16.3)**96(33.9)74(26.1)67(23.7)Theophylline and omeprazole64(22.6)77(27.2)**97(34.3)**45(15.9)Sulfinpyrazone and warfarin110(38.9)**89(31.4)**26(9.2)58(20.5)Meperidine and phenelzine**125(44.2)**54(19.1)39(13.8)65(23.0)Fluconazole and phenytoin109(38.5)**107(37.8)**44(15.5)23(8.1)Warfarin and nortriptyline74(26.1)**146(51.6)**32(11.3)31(11)Amoxicillin and acetaminophen with codeine18(6.4)52(18.4)**197(69.6)**16(5.7)Digoxin and clarithromycin94(33.2)**113(39.9)**54(19.1)22(7.8)Alprazolam and itraconazole**72(25.4)**107(37.8)60(21.2)44(15.5)Dopamine and phenytoin76(26.9)**114(40.3)**36(12.7)57(20.1)Ciprofloxacin and tizanidine**70(24.7)**91(32.2)57(20.1)65(23.0)Cyclosporine and rifampicin102(36.0)**88(31.1)**39(13.8)54(19.1)[^2]

Unfortunately, among the 26 drug pairs, only five of them were identified correctly by most of the participants. To add more 3 out of the 5 pairs had a cutoff of less than 10% between the correct and wrong answer, meaning there still a majority that couldn't identify the correct answer. All the 26 pairs had a statistically significant difference between the correct and incorrect answer ([Table 3](#t0015){ref-type="table"}).Table 3Comparison of correct rate in DDIs knowledge.Drug -- drug combinationsCorrect answer (%)Incorrect answer (%)P valueWarfarin and cimetidine59.740 0.3\<0.0001Sildenafil and isosorbide mononitrate74.625.4\<0.0001Conjugated estrogens and raloxifen27.272.8\<0.0001Fexofenadine HCL and metoprolol43.856.2\<0.0001Theophylline and ciprofloxacin3565\<0.0001Pimozide and ketoconazole32.567.5\<0.0001Methyldopa and phenobarbital17.782.3\<0.0001Phenytoin and cimetidine30.769.3\<0.0001Itraconazole and quinidine37.8.62.2\<0.0001Amiodarone and simvastatin43.156.9\<0.0001Methotrexate and probenecid21.278.8\<0.0001Diphenhydramine and warfarin30.769.3\<0.0001Raloxifene and alendronate32.367.8\<0.0001Warfarin and diflunisal37.562.5\<0.0001Amiodarone and fluconazole16.383.70.0004Theophylline and omeprazole34.365.7\<0.0001Sulfinpyrazone and warfarin31.468.6\<0.0001Meperidine and phenelzine44.255.8\<0.0001Fluconazole and phenytoin37.862.2\<0.0001Warfarin and nortriptyline51.648.4\<0.0001Amoxicillin and acetaminophen with codeine69.630.4\<0.0001Digoxin and clarithromycin39.960.1\<0.0001Alprazolam and itraconazole25.474.6\<0.0001Dopamine and phenytoin40.359.7\<0.0001Ciprofloxacin and tizanidine24.775.3\<0.0001Cyclosporine and rifampicin31.168.9\<0.0001

There were no significant differences were found between age groups, years of practice and country of graduation in knowledge score of DDIs (p \> 0.05) as showed in [Table 4](#t0020){ref-type="table"}.Table 4differences between knowledge scores of CPs with their demographic characteristics.VariablesMean (median)P valueAge25--35 years8.12(7.5)0.7436--45 years9.0(9.0)46--55 years9.8(9.5)  Practice0.12Less than 10 years8.8(9)11--209(9.5)21--309.8(9)31--4013.(11)  Country graduation0.874Egypt8.7(8)Sudan9(9)Yemen9.3(9)Saudi Arabia9.1(10.5)Others9.4(9)

4. Discussion {#s0050}
=============

Despite all implemented and ongoing initiatives, DDIs are still an international problem. Identifying any DDIs is varied based on the practice setting. In an inpatient setting for example, there are different tools that can help in identifying drug interactions and preventing their harm such as electronic systems and accessible scientific resources ([@b0085], [@b0100], [@b0115]). These tools are not available in most community pharmacies in Saudi Arabia. In addition, many medication safety standards are also not available in this setting yet in the country such as look-alike sound-alike and high alert medications list. The lack of electronic systems in community pharmacy setting has a serious impact on both medication and patient safety. Therefore, most of these medication safety standards are carried out by pharmacists' knowledge only.

Based on this study findings, there is a significant lack of information about the major DDIs and other minor interactions. Despite the fact that most of these included medications in this study are available in community pharmacies, most of participated pharmacists could not identify these interactions nor prevent their potential harmful risk. An intervention study was conducted in United States among future health care professionals including pharmacists and medical students reported that they still did not identify potential DDIs after an educational session ([@b0090]). Another cross-sectional study carried out in United States aimed to explore the impact of educational program on DDIs knowledge of health care professionals (medical students, pharmacy and nursing). It revealed that their knowledge scores before educational program were low where students did not classify all DDIs, but after intervention their knowledge scores significant improved ([@b0080]). Moreover, Yu et al. did survey in Singapore among prescribers to assess their knowledge about DDIs. The researchers concluded that prescribers did not identify potential DDIs. However, the lowest percentage was 18.2% for warfarin with cimetidine and the highest percentage of correct answer was 81.2% for paracetamol with amoxicillin ([@b0110]). In addition, most of these medications can be dispense without a prescription, which diminishes the first safety line (the physician).

The need for an electronic system that can detect any DDIs or allergies is essential in the community pharmacy setting. By exploring the country's transformation plan, e-prescription system will be introduced soon and along with that community pharmacies should have electronic systems that can provide different safety tools ([@b0100], [@b0125], [@b0135]). In addition, community pharmacies should have specific courses in drug interactions to cover the most possible interactions that can be seen in this setting. Also, community pharmacists should complete specific number of continuous education hours in patient and medication safety in this setting annually. Furthermore, available and accessible scientific databases and resources should be available for all community pharmacists to check for interactions or any other safety or efficacy measurements. Further studies to investigate the impact of electronic systems and other safety requirements implementation in community pharmacies in Saudi Arabia are required to help improving patient and medication safety in this setting.

In conclusion, the results of this study showed that knowledge of community pharmacists about DDIs was inadequate. Further continues education and electronic systems can help CPs in detecting such interactions easily.
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[^1]: Numbers and percentage don't add up to total (100%) due to missing data.

[^2]: Bold numbers are the corrected answers.
